SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in profiling T- and B-cell receptors of the adaptive immune system, and Nature Immunology, Nature Medicine, Nature Biotechnology and Nature Genetics are proud to be presenting the 2nd annual A Nature Conference: Immune Profiling in Health and Disease, October 3-5, 2016 in Seattle, Washington. This unprecedented conference brings together leading experts from around the world to discuss the clinical and research applications that can arise from immunosequencing and other high-dimensional technologies. This year’s unique program will cover topics including vaccine design, microbiome-host immune cell crosstalk, technological and computational advances, and immune profiling in cancer. The prestigious program has attracted 24 world-class speakers and over 200 scientists from 20 different countries. Keynote presentations will be given by Antonio Lanzavecchia, M.D., Institute for Research in Biomedicine, Switzerland, and Carl June, M.D., University of Pennsylvania.
Next-generation sequencing and other high-throughput immune profiling technologies have revolutionized the characterization of human immune responses. It is now possible to interrogate what constitutes a healthy immune system and how infection, vaccination or disease alters immune cell repertoires and functional activities. Insights gained from high-dimensional profiling of the immune system can aid therapeutic design and treatment strategies in oncology and hematology as well as autoimmune and infectious diseases.
“We continue to see this dynamic field of science and research propel medicine towards better patient care,” said Harlan Robins, Chief Scientific Officer and Co-Founder, Adaptive Biotechnologies. “We are thrilled to once again have the world’s leading scientists attend this immune profiling forum to discuss how medical breakthroughs and technical advancements are helping each other provide a better understanding of diseases and how best to treat them.”
About Adaptive Biotechnologies®
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
